BVXV - ビオンドバックス・ファ―マス―ティカルズ （BiondVax Pharmaceuticals Ltd.） ビオンドバックス・ファ―マス―ティカルズBVXVのチャート
BVXVの企業情報
| symbol | BVXV |
|---|---|
| 会社名 | BiondVax Pharmaceuticals Ltd （ビオンドバックス・ファ―マス―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | ― 医療関連（Health Care） |
| 概要 | 事業概要 -- ビオンドバックス・ファ―マス―ティカルズは、イスラエルのバイオ医薬品企業。感染症の免疫調節療法に焦点をあて、臨床段階の医薬品の開発および実用化に従事。製品候補M-001は合成ペプチドベ―スのタンパク質で、季節的なインフルエンザウイルスと流行性インフルエンザウイルスの両方を標的に長期的な保護を提供するよう設計、開発を行う。 BiondVax Pharmaceuticals Ltd. is a biopharmaceutical company focused on development and manufacturing of products for the prevention of infectious diseases. The Company had been developing M 001, a novel flu vaccine candidate that was designed to provide multi-strain and multi-season protection against current and future, seasonal and pandemic influenza. In seven Phase 1/2 and Phase 2 clinical trials designed to test for immunogenicity, the Company was able to demonstrate M-001 was effective in stimulating an immune response to a broad range of flu strains. In October 2020, the Company completed a Phase 3 clinical trial of M 001 which failed to meet the trial’s primary and secondary efficacy endpoints. The company is now pursuing opportunities in the infectious disease space, including exploring several alternatives for development of a pipeline of assets. |
| 本社所在地 | 14 Einstein Street Ness Ziona 74036 ISR |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | ― |
| 設立年月日 | 37803 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2015年 |
| 従業員数 | － |
| url | www.biondvax.com |
| nasdaq_url | https://www.nasdaq.com/symbol/bvxv |
| adr_tso | 5675763 |
| EBITDA | EBITDA ー |
| 終値（lastsale） | 5.59 |
| 時価総額（marketcap） | 31727515.17 |
| 時価総額 | 時価総額 ― |
| 売上高 | 売上高 -- |
| 企業価値(EV) | 企業価値(EV) ー |
| 当期純利益 | 当期純利益 -- |
| 決算概要 | 決算概要 -- |
BVXVのテクニカル分析
BVXVのニュース
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Receives Buy Rating and $70 Target Price; Releases Q1 2023 and Business Update 2023/05/30 16:00:45 NetworkNewsWire
BiondVax Pharmaceuticals (NASDAQ: BVXV), an innovative biotechnology company developing unique NanoAb immunotherapeutic products for the treatment of infectious disease and large market autoimmune disorders, recently published the financial results for the three months ended March 31, 2023 – Q1 2023 – and provided a business update (https://nnw.fm/qkIoO). The Q1 2023 results were in line with … Continue reading "BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Receives Buy Rating and $70 Target Price; Releases Q1 2023 and Business Update" The post BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Receives Buy Rating and $70 Target Price; Releases Q1 2023 and Business Update appeared first on NetworkNewsWire .
Biondvax Pharmaceuticals GAAP EPS of $0.00 beats by $0.73 2023/05/15 21:56:10 Seeking Alpha
Biondvax Pharmaceuticals press release (BVXV): Q1 GAAP EPS of $0.00 beats by $0.73.As of March 31, 2023, BiondVax had cash and cash equivalents of $10.9 million as compared to…
BiondVax Pharmaceuticals Ltd.: BiondVax Announces First Quarter 2023 Financial Results and Provides Business Update 2023/05/15 20:50:00 Finanz Nachrichten
JERUSALEM, ISRAEL / ACCESSWIRE / May 15, 2023 / (via IBN) -- BiondVax Pharmaceuticals Ltd. (Nasdaq:BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovativ…
BiondVax Announces First Quarter 2023 Financial Results and Provides Business Update 2023/05/15 20:45:00 Accesswire
JERUSALEM, ISRAEL / ACCESSWIRE / May 15, 2023 / (via IBN) -- BiondVax Pharmaceuticals Ltd. (Nasdaq:BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today published its financial results for the first quarter ended March 31, 2023, and provided a business update. First Quarter 2023 Financial Summary R&D expenses for the three months ended March 31, 2023, amounted to $2 million compared with $1.2 million for the three months ended March 31, 2022. The increase of $0.8 million was primarily due to the initiation of R&D activities for the innovative nanosized antibody (NanoAb) platform. Marketing, general and administrative expenses for the three months ended March 31, 2023, amounted to $1.2 million compared with $1.4 million for the three months ended March 31, 2022. Total operating expenses for the three months ended March 31, 2023, amounted to $3.2 million compared with $2.6 for the three months ended March 31, 2022.
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Presents Innovative Pipeline of Nanosized Antibody Treatments at Bio-Europe Spring Conference in Switzerland 2023/04/18 13:00:37 BioMedWire
The EBD Group’s 17th annual Bio-Europe Spring Conference was held March 20-22, 2023, in Basel, Switzerland. The conference showcased three thematic pillars – the business of biotech, therapeutic insight tracks, and ecosystem influencers. The elite European bio-tech conference featured a mix of keynotes from life science executives, fireside chats, panel discussions, and presentations that allowed … Continue reading "BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Presents Innovative Pipeline of Nanosized Antibody Treatments at Bio-Europe Spring Conference in Switzerland" The post BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Presents Innovative Pipeline of Nanosized Antibody Treatments at Bio-Europe Spring Conference in Switzerland appeared first on BioMedWire (BMW) .
Trading - BiondVax Pharmaceuticals Ltd. Sees Large Drop in Short Interest 2022/06/01 16:01:10 Business Mag
BiondVax Pharmaceuticals Ltd. saw a significant drop in short interest in May. As of May 15th, there was short interest totalling 61,600 shares, a drop of 16.4% from the April…
Biondvax Pharmaceuticals reports Q1 results (NASDAQ:BVXV) 2022/06/01 12:44:57 Seeking Alpha
Biondvax Pharmaceuticals press release (BVXV): Q1 GAAP EPS of -NIS0.02.Cash and cash equivalents NIS48.89M.
BiondVax Announces First Quarter 2022 Financial Results and Provides Business Update 2022/06/01 11:10:00 PR Newswire
JERUSALEM, June 1, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceuticals company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today published its…
BiondVax to Present at H.C. Wainwright Global Investment Conference 2022/05/19 15:17:00 PR Newswire
JERUSALEM, May 19, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced that…
Companhia Energetica, Canopy Growth, Tilray Brands among premarket losers'' pack 2022/03/28 12:23:49 Seeking Alpha
Clever Leaves Holdings CLVR -20% after sharp rally last week.Companhia Energetica (CIG) -15%.BiondVax Pharmaceuticals BVXV -9% on FY earnings release.Enservco (ENSV) -8% announces…
Companhia Energetica, Canopy Growth, Tilray Brands among premarket losers'' pack 2022/03/28 12:23:49 Seeking Alpha
Clever Leaves Holdings CLVR -20% after sharp rally last week.Companhia Energetica (CIG) -15%.BiondVax Pharmaceuticals BVXV -9% on FY earnings release.Enservco (ENSV) -8% announces…
Here''s Why Biondvax Pharmaceuticals Shares Are Rising 2022/03/24 15:48:03 Benzinga
Biondvax Pharmaceuticals Ltd - ADR (NASDAQ: BVXV ) shares are trading higher by 32.1% at $1.81 after the company announced it signed a definitive collaboration agreement for the development of a pipeline of innovative nanosized antibody therapies. BiondVax says the company is planning a rapid development path that leverages the company''s expertise and capabilities in biological drug development and manufacturing. BiondVax notes that … Full story available on Benzinga.com
BiondVax, Alpha Tau top healthcare gainers; Sonendo, Creative Medical among losers 2022/03/24 14:01:47 Seeking Alpha
BiondVax Pharmaceuticals BVXV +39%. Alpha Tau Medical (DRTS) +38%. Sonendo (SONX) -11%. Creative Medical Technology (CELZ) -9%.
94.93% Gain Drives BiondVax Pharmaceuticals Ltd. (BVXV) Into Becoming A Interest-Loosing Stock For Investors 2021/12/22 17:00:00 Marketing Sentinel
BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) has a beta value of 2.26 and has seen 100.08 million shares traded in the recent trading session. The company, currently valued at $21.47M, closed the recent trade at $2.88 per share which meant it gained $1.4 on the day or 94.93% during that session. The BVXV stock price is -150.69% 94.93% Gain Drives BiondVax Pharmaceuticals Ltd. (BVXV) Into Becoming A Interest-Loosing Stock For Investors Read More »